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IMPAK PERKHIDMATAN KERJASAMA FARMASI KLINIKAL 
UNTUK PENDOSAN  RENAL TERHADAP PENGUBAHSUAIAN 
DOS  BAGI PESAKIT GINJAL YANG KRONIK 
 
 
ABSTRAK 
 
 Pesakit ginjal kronik sering mengalami perubahan farmakokinetik dan gerak balas 
farmakodinamik. Pesakit ginjal kronik merupakan populasi yang berisiko tinggi 
untuk mendapat kesan mudarat drug dan saling tindak balas drug. Maka dengan itu 
pendosan  drug bagi pesakit-pesakit ini merupakan suatu tanggung jawab yang 
sangat mencabar. Objektif kajian ini adalah untuk menilai impak suatu perkhidmatan 
kerjasama pendosan renal melalui penglibatan ahli farmasi semasa rondaan klinikal 
ke atas pengubahsuaian dos berdasarkan fungsi renal, kejadian kesan mudarat drug 
dan kos drug. Kajian ini juga memerihalkan pola preskripsi dan menentukan 
frekuensi dos yang tidak sesuai bagi pesakit ginjal kronik. Penyelidikan ini 
merupakan suatu kajian perbandingan perspektif intervensi.Sejumlah 600 orang 
pesakit dipilih secara rawak dan dibahagikan kepada dua kumpulan, iaitu 300 orang 
bagi setiap kumpulan. Pesakit yang dipilih untuk kajian adalah pesakit yang 
mempunyai anggaran klearans kreatinin < 50 ml/min. Koleksi rujukan yang dapat 
dipercayai dan kemas kini, serta diguna secara global telah diguna pakai untuk 
dijadikan sebuah buku saku.  Data yang terkumpul sebelum dan selepas intervensi 
dibandingkan. Peratus pesakit lelaki bagi kumpulan praintervensi berbanding 
kumpulan intervensi adalah 56.0% dan 51.0%. Taburan etnik bagi kumpulan 
praintervensi adalah 51.0% Cina, 32.3% Melayu dan 16.0% India. Min umur bagi 
mereka ialah 55.56 ± 14.15 tahun. Kebanyakan pesakit 88.7% memupunyai penyakit 
ginjal tahap hujung (tahap 5). Komobiditi yang sering dihidapi adalah hipertensi 
80.0%, diabetes mellitus 62.3% dan penyakit jantung iskemia 25.7%. Taburan etnik 
 xxii
bagi kumpulan intervensi adalah 40.0% Cina, 44.7% Melayu dan 15.0% India. Min 
umur bagi mereka ialah 55.30 ± 14.37 tahun. Kebanyakan pesakit 93.7% 
memupunyai peuyakit ginjal tahap hujung (tahap 5). Komobiditi yang sering dihidapi 
adalah hipertensi 84.0%, diabetes mellitus 5.6.0% dan penyakit jantung iskemia 
20.7%. Bagi kumpulan praintervensi, min ± SP bilangan ubat yang digunakan di wad 
ialah 9.38 ± 3.63 per pesakit.  Dalam kumpulan  intervensi pula, min bilangan ubat  
yang digunakan di wad ialah 9.94 ± 3.78 per pesakit.  Kelas drug yang paling sering 
digunakan ialah suplemen mineral, vitamin, sediaan antianemik, antibakteria, 
penghalang beta, penghalang saluran kalsium, diuretik, agen pengurangan lipid 
serum, drug untuk diabetes, drug untuk gangguan asid, agen antitrombotik, 
analgesik, dan agen yang bertindak terhadap sistem angiotensin.  Fasa intervensi 
dijalankan oleh ahli farmasi klinikal bermula dari Mac 2008 sehingga Julai 2008. 
Sejumlah 212 (54.6%) cadangan pendosan oleh farmasi daripada 388 cadangan yang 
diberikan telah diterima oleh doctor yang mempreskripsi. Kebanyakan intervensi 
yang diterima melibatkan ranitidin, seftazidim, ampisilin / sulbaktam, amoksisilin / 
klavulanat, metoklopramid, digoksin, atenolol, khlorotiazida, dan amikasin.  Bagi 
kumpulan praintervensi,  pengubahsuaian atau penghindaran dos drug  berdasarkan 
fungsi ginjal diperlukan dalam 607 daripada 2814 (21.6%) preskripsi. Daripada 
jumlah ini, 322 (53.0%) tidak mematuhi garis panduan. Bagi kumpulan intervensi 
pula, pengubahsuaian atau penghindaran dos drug berdasarkan fungsi ginjal 
diperlukan dalam 640 daripada 2018 (21.5%) preskripsi. Dengan adanya 
perkhidmatan kerjsama pendosan ketidakpatuhan dapat dikurangkan kepada 176 
(27.5%) (nilai-p < 0.0001).  Bagi kumpulan praintervensi, 64 (21.3%) pesakit 
dijangkakan mengalami kejadian kesan mudarat drug dengan jumlah 73 peristiwa. 
Jumlah ini berkurangan secara signifikan dalam kumpulan intervensi kepada 49 
 xxiii
peristiwa dalam 48 (16.0%) pesakit (nilai-p < 0.05).   Intervensi mampu menjimatkan 
kos drug sebanyak RM 7760.Tiada perbezaan yang signifikan bagi tempoh berada di 
hospital dan hasil pengubatan bagi diantara kumpulan praintervensi dan intervensi. 
Kami merumuskan bahawa perkhidmatan dos kolaborasi boleh meningkatkan 
pengubahsuaian drug terhadap fungsi ginjal.  Oleh itu, ia mampu menjimatkan kos 
drug dan berpotensi untuk mengelak kejadian kesan mudarat drug. 
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THE IMPACT OF INPATIENT COLLABORATIVE CLINICAL 
PHARMACY RENAL DOSING SERVICE ON DOSAGE 
 ADJUSTMENT IN PATIENTS WITH CHRONIC 
 KIDNEY DISEASE 
 
ABSTRACT 
Patients with chronic kidney disease often have alterations in their pharmacokinetic 
and pharmacodynamic response. They constitute a population at high-risk for 
adverse drug reactions and drug-drug interactions. Drug dosing in these patients is a 
very challenging task. The objectives of this study were to evaluate the impact of an 
inpatient collaborative renal dosing service by pharmacist’s participating in clinical 
rounds on dosage adjustment according to renal function, adverse drug events, and 
drug costs. It aimed also to describe prescribing patterns for hospitalized chronic 
kidney disease patients and to assess the frequency of inappropriate dosing. The 
study was an interventional prospective comparative study. A total of 600 patients 
were randomly selected with 300 patients in each groups. Patients who had an 
estimated creatinine clearance of ≤ 50 ml/min on admission were included. A 
collection of reliable and up-to-date references became the basis of applied pocket 
sized handbook that was used by the clinical pharmacist during medical rounds. Data 
before and during the intervention were compared. The percentages of male patients 
in the pre-intervention and intervention groups were 56.0% and 51.0% respectively. 
In the pre-intervention group 51.0% were Chinese, 32.3% were Malay, and 16.0% 
were Indian. The mean age was 55.56 ± 14.15 years. Most patients 88.7% had end 
stage renal disease (stage 5). The most common co-morbidities were hypertension in 
80.0% of the patients, diabetes mellitus in 62.3%, and ischemic heart disease 25.7%. 
In the intervention group, 40.0% were Chinese, 44.7% were Malay, and 15% were 
Indian. The mean age was 55.30 ± 14.37 years. Most patients 93.7% had end stage 
 xxv
renal disease (stage 5). The most common co-morbidities were hypertension in 
84.0% of the patients, diabetes mellitus in 56.0%, and ischemic heart disease 20.7%. 
In the pre-intervention group, the mean ± SD number of medications used in ward 
during hospitalization was 9.38 ± 3.63 per patient, whereas in the intervention group, 
the mean ± SD number of medications used in ward during hospitalization was 9.94 
± 3.78 per patient. The most commonly used medication classes were mineral 
supplements, vitamins, anti-anemic preparations, anti-bacterials, beta blockers, 
calcium channel blockers, diuretics, serum lipid reducing agents, drugs used in 
diabetes, drugs for acid-related disorders, anti-thrombotic agents, analgesics, and 
agents acting on the renin angiotensin system. The intervention was performed by a 
clinical pharmacist from March to July 2008. Out of  388 dosing recommendations 
given by the pharmacist, the prescribers accepted a total of 212 recommendations 
(54.6%). The most commonly accepted interventions were with ranitidine, 
ceftazidime,  ampicillin/sulbactam,  amoxicillin/clavulanate, metoclopramide, 
digoxin, atenolol, chlorothiazide, and amikacin. In the pre-intervention group, drug 
dosage adjustments or avoidance based on renal function was necessary in 607 of 
2814 (21.6%) of prescriptions. Out of these, 322 (53.0%) did not comply with 
guidelines. In the intervention group, dosage adjustment or avoidance based on renal 
function was necessary in 640 of 2981 (21.5%) of prescriptions. During the 
collaborative dosing service, noncompliance significantly decreased to 176 (27.5%) 
(p-value < 0.0001). In the pre-intervention group, 64 (21.3%) patients had a 
suspected adverse drug event with a total of 73 events. The number significantly 
decreased in the intervention group to 49 events in 48 ( 16.0%) patients (p-value < 
0.05). The intervention caused savings in drug cost of  RM 7760. There was no 
significant difference in length of hospital stay and outcomes of hospitalization 
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between the pre-intervention and the intervention group. We concluded that the 
inpatient collaborative clinical pharmacy dosing service can increase the proportion 
of drugs adjusted to renal function. This can save drug costs and has the potential to 
prevent adverse drug events. 
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 Chronic kidney disease 
1.1.1 Background 
Chronic kidney disease (CKD) is a worldwide public health problem with an 
increasing incidence and prevalence, poor outcomes, and high cost (National Kidney 
Foundation, 2002). It is a progressive and irreversible loss of patient’s kidney 
function occurring over several months to years, and is characterized by the gradual 
replacement of normal kidney architecture with interstitial fibrosis (Ashley and 
Morlidge, 2008).  
 
It is a worldwide problem affecting more than 50 million people, and more than 1 
million of them are receiving kidney replacement therapy. In the United States of 
America (USA), it is estimated that CKD affects 11% of the USA population, and 
those affected are at increased risk of cardiovascular disease (CVD) and kidney 
failure. Kidney failure represents about 1% of the prevalent cases of CKD in the 
USA, and the prevalence of kidney failure treated by dialysis or transplantation is 
projected to increase to 651,000 in 2010 (National Kidney Foundation, 2007a). In 
Malaysia, the number of prevalent dialysis patients also increased linearly from 4540 
in 1998 to almost more than 16000 by the end of 2007. Dialysis prevalence rate 
continued to increase linearly over the last 10 years, from 205 per million population 
in 1998 to at least 615 in 2007 (Lim YN and Lim TO, 2008). The incidence and 
prevalence of the disease have doubled in the past decade, most likely because of 
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improved treatments for hypertension, diabetes mellitus, and coronary disease have 
increased longevity in affected patients and, therefore, their likelihood of developing 
CKD (Snively and Gutierrez, 2004).  
 
The major outcomes of CKD regardless of the specific diagnosis  include 
progression to kidney failure, complications from decreased kidney function, and 
development of CVD (Johnson et al., 2004). Unfortunately, CKD is “under-
diagnosed” and “under-treated”,  this has led to attempts to improve both the 
detection and management of patients with impaired renal functions (Macgregor et 
al., 2006). A growing body of evidence suggests that some of the adverse outcomes 
of CKD can be prevented or delayed. At each stage patients can benefit from 
measures that delay or prevent the progressive loss of renal function, modification of 
medications with renal clearance, avoidance of nephrotoxins, and reduction of 
cardiovascular risk factors. Early diagnosis, treatment of comorbid conditions, 
management of complications, education and preparation for kidney replacement 
therapies have all been associated with better outcomes (Joy et al., 2005; McClellan, 
2005; National Kidney Foundation, 2007a). 
 
1.1.2 Definition and stages of chronic kidney disease 
Glomerular filtration rate (GFR) is the best measure of overall kidney function in 
health and disease. The normal level of GFR varies according to age, sex, and body 
size. Normal GFR in young adults is approximately 120 to 130 ml/min/1.73 m2 
(National Kidney Foundation, 2002). A GFR level of less than 60 ml/min/1.73 m2 
represents loss of half or more of the adult level of normal kidney function. Below 
this level, the prevalence of complications of CKD increases (Levey et al., 2003).  
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In 2002, the Kidney Disease Outcomes Quality Initiative (KDOQI) of the National 
Kidney Foundation (NKF) established a classification system for CKD that had been 
accepted and used worldwide. This classification defines CKD as a GFR of less than 
60 ml/min/1.73 m² for three months or more, with or without kidney damage or 
kidney damage for three or more months, as defined by structural or functional 
abnormalities of the kidney, with or without decreased GFR, manifested by either: 
pathologic abnormalities, or markers of kidney damage, including abnormalities in 
the composition of the blood or urine or abnormalities in imaging tests. Disease stage 
should be assigned based on the occurrence of kidney damage and the level of 
kidney function, regardless of the specific diagnosis. Based on this definition, the 
KDOQI has recommended a classification of CKD into five stages with clinical 
action plan as shown in the following table  (National Kidney Foundation, 2002). 
 
Table 1.1. Chronic kidney disease staging and clinical action plan 
Stage Description GFR 
ml/min/1.73m² 
Action* 
1 Kidney damage 
with normal or 
↑GFR 
≥ 90 Diagnosis and treatment. 
Treatment of comorbidities. 
Slowing progression. 
CVD risk reduction. 
 
2 Kidney damage 
with mild ↓ GFR 
 
60-89 Estimating progression. 
3 Moderate ↓ GFR 30-59 Evaluating and treating 
complications. 
 
4 Severe ↓ GFR 15-29 Preparation for kidney 
replacement therapy. 
 
5 Kidney failure 
( ESRD) 
<15  
( or dialysis) 
 
Replacement ( if uremia present). 
* Includes actions from preceding stages, GFR: glomerular filtration rate, CVD: 
cardiovascular disease, ESRD: end-stage renal disease. 
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Although the age-related decline in GFR has been considered part of normal aging, 
decreased GFR in the elderly is an independent predictor of adverse outcomes, such 
as death and CVD. In addition, decreased GFR in the elderly requires adjustment in 
drug dosages, as in other patients with CKD. Therefore, the definition of CKD is the 
same, regardless of age (Levey et al., 2003). 
 
1.1.3 Causes  and risk factors for chronic kidney disease  
Risk factors identified for CKD are classified into three categories: 
Susceptibility factors: which are associated with an increased risk of developing 
CKD, but are not directly proven to cause it. These factors are generally not 
modifiable by pharmacologic therapy or lifestyle modifications. The factors include 
advanced age, reduced kidney mass, low birth weight, family history of kidney 
disease, low income or education, systemic inflammation, and dyslipidemia (Lederer 
and Ouseph, 2007; Chisholm-Burns et al., 2008). 
 
Initiation factors: are factors or conditions that directly initiate kidney damage, and 
are modifiable by pharmacologic therapy. These factors include diabetes mellitus, 
hypertension, autoimmune diseases, polycystic kidney disease, systemic infections, 
urinary tract infections, urinary stones, lower urinary tract obstructions, and drug 
toxicity  (DiPiro et al., 2005; Chisholm-Burns et al., 2008). 
 
Progression factors: which result in a faster decline in kidney function and cause 
worsening of CKD. These factors may also be modified by pharmacologic therapy or 
lifestyle modifications to slow the progression of CKD. They include proteinuria, 
 5
poor blood glucose control in patients with diabetes, elevated blood pressure, and 
tobacco smoking (Chisholm-Burns et al., 2008).  
 
1.1.4 Clinical presentation of chronic kidney disease 
The development of CKD is usually subtle in onset, often with no noticeable 
symptoms. Stage 1 and 2 CKD are generally asymptomatic. Symptoms usually 
appear with advanced stages of the disease. Stage 3 and 4 CKD may be associated 
with minimal symptoms. Typical symptoms and signs associated with stage 5 CKD  
include fatigue, electrolyte disturbances, hypertension, pruritis, ‘restless leg’ 
syndrome, anorexia, nausea, vomiting, and bleeding abnormalities as well as those of 
anemia and of renal bone disease (Ashley and Morlidge, 2008; Chisholm-Burns et 
al., 2008). 
 
Laboratory tests abnormalities include increased blood urea nitrogen, serum 
creatinine, and decreased GFR. With advanced stages patients have increased 
potassium, phosphorus, and magnesium. Calcium levels are generally low in earlier 
stages of CKD and may be elevated in stage 5 CKD, secondary to the use of calcium 
containing phosphate binders. Hematological abnormalities include decreased red 
blood cells count, hemoglobin, and hematocrit. Other abnormalities include 
increased  parathyroid hormone (PTH) levels and decreased vitamin D levels (stage 4 
and 5 CKD) (Chisholm-Burns et al., 2008). 
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1.2 Pharmacotherapy interventions in chronic kidney disease management 
Treatment of CKD should include (National Kidney Foundation, 2002): 
• Specific therapy, based on diagnosis. 
• Evaluation and management of comorbid conditions. 
• Slowing the loss of kidney function. 
• Prevention and treatment of CVD. 
• Prevention and treatment of complications of decreased kidney function. 
• Preparation for kidney failure and renal replacement therapy. 
• Replacement of kidney function by dialysis and transplantation, if signs and 
symptoms of uremia are present. 
 
After the detection of CKD, treatment of comorbid conditions, interventions to slow 
progression of kidney disease, and measures to reduce the risk for CVD should begin 
during stage 1 and stage 2. Hypertension is both a cause and a complication of CKD 
and should be carefully controlled in all patients. Evaluation and treatment of other 
complications of CKD, such as anemia, malnutrition, bone disease, neuropathy, and 
decreased quality of life, should be undertaken during stage 3, as the prevalence of 
these complications begins to rise when GFR declines to less than 60 ml/min/1.73 
m2.  Preparation for kidney replacement therapy should begin during stage 4, well 
before the stage of kidney failure. Initiation of dialysis and transplantation is 
triggered by the onset of uremic symptoms. Preparations for these treatments should 
begin when GFR declines to less than 15 ml/min/1.73 m2 (stage 5). The clinical 
action plan for each stage should include actions begun in preceding stages. The 
earlier these measures are implemented, the greater is their success rate (Levey et al., 
2003; Macgregor et al., 2006).  
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Medications prescribed to patients should be reviewed. Dosage adjustments should 
be based on the level of kidney function. It is important to detect drug interactions, as 
well as potentially adverse effects of medications on kidney function or 
complications of CKD. If possible, therapeutic drug monitoring should be performed 
in patients with CKD (Johnson et al., 2004). 
 
1.2.1 Prevention or slowing the loss of kidney function 
The rate of progression for CKD depends on the underlying cause. In general, 
tubulointerstitial diseases progress more slowly than do glomerular diseases, diabetic 
and hypertensive nephropathy, and polycystic kidney disease. Rates of progression 
also vary widely among patients with the same type of kidney disease. In rapidly 
progressing kidney disease, the GFR may decrease by as much as 10 to 20 
ml/min/1.73 m2 per year. In more slowly progressing disease, the GFR may decrease 
by as little as 2 ml/min/1.73 m2 per year. Plotting the GFR against time is helpful in 
estimating the rate of disease progression and the time to kidney failure, and it helps 
predict the need for kidney replacement therapy (Snyder and Pendergraph, 2005).  
 
Three interventions have been proved to slow the progression of kidney disease: 
blood pressure control, glycemic control in patients with diabetes, and reduction of 
proteinuria with an angiotensin converting enzyme (ACE) inhibitor or  angiotensin 
receptor blocker (ARB). Other interventions that may be beneficial include lipid-
lowering measures, partial correction of anemia, limiting dietary protein intake, 
weight loss, and smoking cessation (McClellan, 2005; Snyder and Pendergraph, 
2005).  
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Attempts should be made to prevent and correct acute decline in GFR. Frequent 
causes of acute decline in GFR include; volume depletion, IV radiographic contrast, 
selected antimicrobial agents (e.g., aminoglycosides, amphotericin B), nonsteroidal 
anti-inflammatory drugs, including cyclo-oxygenase 2 inhibitors, ACE inhibition,  
angiotensin-2 receptor blockers, cyclosporine, tacrolimus, and obstruction of the 
urinary tract (National Kidney Foundation, 2002). 
 
Proteinuria is associated with more rapid progression of CKD and a greater 
likelihood of developing ESRD. Consequently, detection and quantitation of 
proteinuria are essential for the diagnosis and treatment of CKD. Microalbuminuria 
is defined as an albumin-creatinine ratio of 30–300 mg/g from a spot urine 
collection, 30–300 mg/24 hours in a 24-hour urine collection, or 20–200 mg/min in a 
timed urine collection. Macroalbuminuria is defined as > 300 mg/g, > 300 mg/24 
hours, and > 200 mg/min in the same tests, respectively (Snyder et al., 2005; 
Cavanaugh, 2007). 
 
The role of dietary protein restriction in chronic renal disease remains controversial. 
The largest controlled study initially failed to find an effect of protein restriction, but 
secondary analysis based on achieved protein intake suggested that a low protein diet 
slowed the progression (Parmar, 2002). It is recommended to restrict protein intake 
0.60 to 0.75 g/kg of body weight per day in patients with a GFR below 25 
ml/min/1.73 m2. Malnutrition is common in patients with end stage renal disease 
(ESRD) for various reasons, including decreased appetite, hypercatabolism, and 
nutrition losses through dialysis. For this reason, patients receiving dialysis should 
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maintain protein intake of 1.2-1.3 g/kg per day (McClellan, 2005; Chisholm-Burns et 
al., 2008). 
 
Smoking, besides increasing the risk of cardiovascular events, is an independent risk 
factor for development of ESRD in patients with kidney disease. Recently, several 
small observational studies have reported that smoking cessation is associated with 
reduced risk of progressive renal injury, suggesting that smoking should be 
considered a risk factor for progressive renal insufficiency and cessation may be 
renoprotective and beneficial to general and cardiovascular health (Parmar, 2002; 
McClellan, 2005).  
 
There is growing evidence that obesity may be a risk factor for progressive renal 
injury (McClellan, 2005). Exercise even without change in body mass index may 
decrease proteinuria (Lederer and Ouseph, 2007). 
 
 
1.2.2 Prevention and treatment of cardiovascular disease 
Cardiovascular disease is the most common cause of death in patients with CKD. 
The risk of CVD and associated mortality increases in proportion to the decrease in 
the GFR. Patients with albuminuria and normal GFR also are at increased risk. 
Indeed, recent studies show that patients with CKD are 100 times more likely to die, 
principally of CVD, than to develop kidney failure (Keith et al., 2004).  
 
Evaluation for traditional cardiovascular risk factors, including smoking, high lipid 
levels, hypertension, and sedentary lifestyle, is essential. The KDOQI guidelines 
recommend a blood pressure goal of 130/80 mm Hg in patients with normal urinary 
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albumin concentrations, and a blood pressure goal of 125/75 mm Hg in patients with 
excretion of more than 1 g of protein per 24 hours.  
 
The KDOQI guidelines on managing dyslipidemias in CKD recommend a low-
density lipoprotein (LDL) cholesterol goal of less than 100 mg/ dL (2.60 mmol/L) 
for patients with CKD, because they are statistically at highest risk for CVD 
(National Kidney Foundation, 2003a). 
 
Additional cardiac risk factors specific to CKD include volume overload, 
hyperparathyroidism, and uremia. Anemia caused by decreased erythropoietin 
production also may contribute to cardiovascular mortality. Treatment with 
exogenous erythropoietin has been shown to improve the prognosis (Snyder and 
Pendergraph, 2005). 
 
The medical management of chronic CAD in CKD and dialysis patients should 
follow that of the general population. Patients should receive acetylsalicylic acid, 
beta-blockers, nitroglycerin, ACE inhibitors or ARBs, statins, and/or calcium 
channel blockers (CCB) as indicated. Dose adjustments are required for medications 
that are renally excreted or dialyzed (National Kidney Foundation, 2005). 
 
1.2.3 Treatment of Comorbidities  
1.2.3.1 Hypertension  
Hypertension is the second most common cause of ESRD. Elevated blood pressure is 
also an important modifiable risk factor for progressive CKD regardless of the initial 
cause of kidney injury. Evidence from clinical trials shows that blood pressure 
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reduction reduces the rate of loss of renal function and progression to renal failure 
(Parmar, 2002; McClellan, 2005).  
 
Systemic hypertension causes direct damage to small blood vessels in the nephron. 
The kidneys lose their ability to autoregulate glomerular filtration flow and pressure, 
with resultant hyperfiltration manifesting as albuminuria and proteinuria. When the 
proximal convoluted tubule reabsorbs the excess protein, secretion of vasoactive 
substances further damages the glomerular-tubular apparatus. Nephron damage 
activates the renin-angiotensin-aldosterone system, resulting in increased 
sympathetic tone and fluid overload, which compound the progression of 
hypertension and nephron loss (Snively and Gutierrez, 2004). 
 
The seventh report of the Joint National Committee (JNC7) recommends a target 
blood pressure of less than 130/80 mm Hg in patients with CKD (Snively and 
Gutierrez, 2004). The NKF-KDOQI guidelines recommend a target blood pressure of 
less than 130/80 mm Hg in patients with stage 1 through 4 CKD (National Kidney 
Foundation, 2004). Stage 5 CKD patients who are receiving hemodialysis (HD) 
should achieve a goal blood pressure of less than 140/90 mm Hg before hemodialysis 
and less than 130/80 mm Hg after hemodialysis (Chisholm-Burns et al., 2008). 
 
Dietary sodium intake of < 2.4 g/d (<100 mmol/d) should be recommended in most 
adults with CKD and hypertension. ACE inhibitors and ARBs preferentially lower 
intraglomerular pressure and reduce proteinuria. Evidence from both animal models 
of renal injury and clinical trials shows that blockade of the renin-angiotensin system 
with ACE inhibitors and ARBs reduces the risk of progressive renal injury 
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(McClellan, 2005; National Kidney Foundation, 2007a). Efficacy may be increased 
when these agents are given in combination. Agents that block the renin-angiotensin 
system should be first-line drugs for the management of hypertension. When ACE 
inhibitor therapy is started, some patients with CKD may have an initial decrease in 
GFR (usually less than 10 ml/min/1.73 m2), a mild increase in the serum creatinine 
concentration (less than 20% of the baseline value), and a mild increase in the 
potassium level (usually less than 0.5 mmol/L). Therefore, serum creatinine and 
potassium levels should be monitored one to two weeks after an ACE inhibitor was 
initiated. It is recommended to reduce or discontinue ACE inhibitoe if serum 
potassium consistently exceeds 5.5 mg/dL or if renal function reduces more than 
30% of baseline within 4 months (Snively and Gutierrez, 2004; McClellan, 2005; 
Lederer and Ouseph, 2007). 
 
Non-dihydropyridine calcium channel blockers have also been shown to retard 
progression of renal insufficiency in patients with type 2 diabetes (Parmar, 2002). As 
decline in kidney function progresses, the effect of thiazide diuretics for blood 
pressure control may lessen and the potential for electrolyte disturbances may 
increase. Therefore, it is generally recommended that, for patients with a GFR < 30 
ml/min/1.73 m2, thiazide diuretics should be replaced with loop diuretics. Potassium-
sparing diuretics should be used with caution with GFR <30 ml/min/1.73m2 (CKD 
stages 4–5), in people receiving concomitant therapy with ACE inhibitors or ARBs, 
and in people with additional risk factors for hyperkalemia (Cavanaugh, 2007; 
National Kidney Foundation, 2004).  
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1.2.3.2 Diabetes mellitus 
Diabetes is the most common cause of kidney disease. From 40 to 60 % of patients 
who progress to ESRD have diabetes (Snyder and Pendergraph, 2005).  
Hyperglycemia is an independent risk factor for nephropathy. The pathophysiology 
of diabetic nephropathy is complex and most likely involves both hemodynamic and 
glucose-dependent factors, including the accumulation of advanced glycated 
products, endothelial dysfunction, and loss of intraglomerular blood pressure 
regulation (Snively and Gutierrez, 2004). Studies have shown that glycemic control 
reduces the progression of kidney disease. The target Hb A1c concentration should 
be below 7%, irrespective of the presence or absence of CKD (National Kidney 
Foundation, 2007a). Yearly screening for microalbuminuria and blood pressure 
control with an ACE inhibitor or ARB is recommended (Snively and Gutierrez, 
2004). 
 
Patients with decreased kidney function (stage 3 to 5) have increased risk of 
hypoglycemia for two reasons: (1) decreased clearance of insulin and some of the 
oral agents used to treat diabetes, and (2) impaired kidney glucogenesis that may 
decrease the ability of the patient to defend against hypoglycemia. About one third of 
insulin degradation is carried out  by the kidney. However, when there is impairment 
of kidney function, the half-life of insulin is prolonged because of lower levels of 
degradation. Therefore, in patients with moderate to severe kidney dysfunction, the 
frequency of hypoglycemic episodes may be as much as five times that of patients 
without kidney disease. Caution must be exercised when administering therapy to 
patients with kidney disease, and frequent blood glucose monitoring may be used to 
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adjust dosing and prevent hypoglycemia (National Kidney Foundation, 2007a; 
Cavanaugh, 2007).  
 
The NKF-KDOQI guidelines have mentioned special considerations in drug therapy. 
For oral hypoglycemic agents, the clearance of both sulfonylureas and their 
metabolites is highly dependent on kidney function, and severe prolonged episodes 
of hypoglycemia as a result of sulfonylurea use have been described in dialysis 
patients. In patients with stage 3–5 CKD, first-generation sulfonylureas should be 
avoided. Of the second-generation sulfonylureas, glipizide and gliclazide are 
recommended because their metabolites are not active, and there is a lower potential 
for development of hypoglycemia. In the meglitinide class, nateglinide has increased 
active metabolites with decreased kidney function, but these don’t occur with 
repaglinide. Although the mechanisms are not clear, alpha-glucosidase inhibitors and 
metabolites may result in damage from cumulative dose effects and result in possible 
hepatic damage. Therefore, this class of medications is not recommended for patients 
with a serum creatinine > 2 mg/dl. Metformin is in the biguanides class of oral 
hyperglycemic drugs, which does not exhibit the high risk of hypoglycemia 
associated with other drug classes used to treat diabetes. However, there is a risk of 
development of lactic acidosis, even in patients with mild impairment of kidney 
function, again likely resulting from the accumulation of the drug and its metabolites. 
Metformin is contraindicated in male patients with a serum creatinine > 1.5 mg/dl 
and in female patients with serum creatinine > 1.4 mg/dl. Recently, it has been 
suggested that thiazolidinediones (TZDs) may have a protective effect to either 
prevent or slow the progression of CKD independent from glycemic control. Several 
small studies have reported a greater reduction in albuminuria in patients 
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administered TZDs; however, there has been no evidence to support an independent 
association between TZD use and actual prevention of CKD. This class of drugs 
undergoes hepatic metabolism. It has been demonstrated to be effective without 
increasing the risk of hypoglycemic episodes in patients with CKD, including those 
receiving dialysis. No adjustment in dosing of TZDs is required for these patient 
groups (National Kidney Foundation, 2007a; Cavanaugh, 2007).  
 
1.2.3.3 Dyslipidemia  
Dyslipidemia is a primary risk factor for cardiovascular disease and a common 
complication of progressive kidney disease. Most patients with CKD have an 
abnormal lipid panel that increases their risk for atherogenesis. Dyslipidemia 
contributes to cardiovascular mortality, which is 10 to 20 times higher in dialysis 
patients than in the normal population even after adjustments are made for age, sex, 
and diabetes mellitus. 
 
The most noticeable lipid abnormality in CKD is an elevated triglyceride level, 
possibly because of defective clearance. Patients with CKD also have an elevated 
ratio of low-density lipoprotein (LDL) cholesterol to high-density lipoprotein (HDL) 
cholesterol. LDL cholesterols, including lipoprotein(a), are pro-atherogenic, and 
levels are slightly elevated in patients with CKD. Levels of oxidized LDL cholesterol 
are also elevated; these cholesterols activate pro-inflammatory pathways, thereby 
promoting atherogenesis and endothelial dysfunction. HDL cholesterol levels are 
decreased, indicating loss of anti-atherogenic effect (Snively and Gutierrez, 2004). 
 
 16
The most recent guidelines from the NKF-KDOQI  recommend treating dyslipidemia 
aggressively in patients with CKD. The goals are a LDL cholesterol level below 100 
mg/dL (2.60 mmol/L) and a triglyceride level below 200 mg/dL (2.26 mmol/L). 
Fibrates are known to decrease triglyceride levels, but they may increase the risk for 
rhabdomyolysis in patients with CKD. Statins can lower cholesterol levels safely and 
effectively in these patients (National Kidney Foundation, 2003a, Snively and 
Gutierrez, 2004). 
 
1.2.4 Treatment of complications of chronic and end stage renal disease 
1.2.4.1 Anemia 
Anemia develops early in the course of CKD and is nearly universal in patients with 
CKD stage 5. The prevalence of anemia is correlated with the degree of renal 
dysfunction. More than 26% of patients with a GFR greater than 60 ml/min/1.73 m2 
are estimated to have anemia, and the number increases with a GFR of less than 15 
ml/min/1.73 m2 (Chisholm-Burns et al., 2008).  
 
In the opinion of the work group of the NKF, hemoglobin (Hb) testing should be 
carried out in all patients with CKD, regardless of stage or cause. Hb levels should be 
measured at least annually. Diagnosis of anemia should be made and further 
evaluation should be undertaken at Hb concentrations less than 13.5 g/dL in adult 
males and less than 12.0 g/dL in adult females (National Kidney Foundation, 2006). 
In dialysis and nondialysis patients with CKD receiving erythropoiesis stimulating 
agent (ESA) therapy, the selected Hb target should generally be in the range of 11.0 
to 12.0 g/dL. The Hb target should not be greater than 13.0 g/dL. Patients with 
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plasma ferritin concentrations below 100 ng/mL should be given iron supplements 
(National Kidney Foundation, 2007b).  
 
Anemia of chronic renal disease begins when the GFR falls below 30-35% of normal 
and it is normochromic and normocytic. This is primarily caused by decreased 
production of erythropoietin by the failing kidney as the progenitor cells of the 
kidney produce 90% of the hormone erythropoietin, but other potential causes 
include blood loss through frequent blood draw and increased tendency toward 
gastrointestinal bleeding due to diminished platelet function and decreased red blood 
cell lifespan from a normal of 120 days to as low as 60 days in patients with stage 5 
CKD. Whether anemia accelerates the progression of renal disease is controversial. 
However, it is independently associated with the development of left ventricular 
hypertrophy and other cardiovascular complications. Treatment of anemia results in 
partial regression of left ventricular hypertrophy in both patients with pre-end stage 
renal disease and patients receiving dialysis and has reduced the frequency of heart 
failure, hospitalization and mortality among patients receiving dialysis (Parmar, 
2002; Lederer and Ouseph, 2007; Chisholm-Burns et al., 2008). 
 
Generally, treatment requires a combination of ESA and iron supplementation. 
Erythropoietin should be administered to predialysis patients who have anemia-
dependent angina or severe anemia with a hemoglobin concentration below 10 g/dL. 
Hypertension and an increased risk for thrombotic events are potential adverse 
effects of treatment. Therefore, patients receiving erythropoietin must be monitored 
closely (Snively and Gutierrez, 2004). Subcutaneous (SC) administration is 
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recommended  for patients not on HD and IV route can be used in HD patients 
(National Kidney Foundation, 2006). 
 
Oral iron supplements are less costly than IV supplements and are generally the first 
line treatment. Oral iron supplementation is generally not effective in maintaining 
adequate iron stores in patients receiving ESAs because of poor absorption and 
increased iron need, making the IV route necessary. The IV route is recommended by 
the NKF for HD patients while either oral or IV route can be used for non dialysis or 
peritoneal dialysis (PD) patients. The goal of treatment for anemia of CKD is to 
increase Hb levels to greater than 11 g/dL. The goal of iron supplementation is to 
maintain serum ferritin levels between 100-500 ng/mL in patients not receiving HD 
and between 200-500 ng/mL in patients receiving HD and total saturation greater 
than 20% (Chisholm-Burns et al., 2008). 
 
1.2.4.2 Renal osteodystrophy 
Changes in mineral metabolism and bone structure begin early in CKD. These 
changes include osteitis fibrosa cystica (because of secondary hyperparathyroidism); 
less commonly, osteomalacia (defective mineralization); and adynamic bone disease 
(absence of cellular activity). Osteitis fibrosa cystica, the predominant bone defect, is 
characterized by an increase in bone turnover that leads to decreased cortical bone 
and impaired bone strength. Bone disease can result in pain and an increased risk of 
fracture. 
 
In patients wih CKD (stages 3 and 4), the serum level of phosphorus should be 
maintained at or above 2.7 mg/dL (0.87 mmol/L) and no higher than 4.6 mg/dL (1.49 
 19
mmol/L). In patients with CKD with kidney failure (stage 5) and those treated with 
HD or PD, the serum levels of phosphorus should be maintained between 3.5 and 5.5 
mg/dL (1.13–1.78 mmol/L). The preferred phosphate binder are calcium-based 
phosphate binders. The total dose of elemental calcium provided by the calcium-
based phosphate binders should not exceed 1500 mg/day, and the total intake of 
elemental calcium (including dietary calcium) should not exceed 2000 mg/day. 
Calcium-based phosphate binders should not be used in people on dialysis who are 
hypercalcemic (corrected serum calcium of 10.2 mg/dL [2.54 mmol/L]), or whose 
plasma parathyroid hormone levels are <150 pg/mL (16.5 pmol/L) on two 
consecutive measurements (National Kidney Foundation, 2003b). 
 
Parathyroid hormone levels begin to rise when creatinine clearance falls below 60 
ml/min. The development of hyperparathyroidism may be prevented by restricting 
dietary phosphate intake (e.g., colas, nuts, peas, beans, dairy products), using a 
calcium-based phosphate binder with meals, and administering vitamin D  to 
suppress parathyroid hormone secretion (Parmar 2002). In people with CKD (stages 
3 and 4) who have plasma levels of intact PTH >70 pg/mL (7.7 pmol/L; stage 3) or 
>110 pg/mL (12.1 pmol/L; stage 4) on more than two consecutive measurements, 
dietary phosphate intake should be restricted. If this is ineffective in lowering plasma 
PTH levels, calcitriol or one of its analogs (alfacalcidol or doxercalciferol) should be 
given to prevent or ameliorate bone disease. In people with CKD (stage 5) who have 
elevated plasma levels of intact PTH (>300 pg/mL [33.0 pmol/L]), calcitriol or one 
of its analogs (doxercalciferol, alfacalcidol or paricalcitol) should be used to reverse 
the bone features of PTH overactivity (i.e., high-turnover bone disease) and to treat 
defective mineralization (National Kidney Foundation, 2003b). 
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Even with appropriate medical therapy, some patients continue to have refractory 
hyperparathyroidism. Parathyroidectomy should be recommended in people with 
severe hyperparathyroidism (persistent serum levels of intact PTH >800 pg/mL [88.0 
pmol/L), associated with hypercalcemia and/or hyperphosphatemia that are 
refractory to medical therapy (National Kidney Foundation, 2003b). 
 
1.2.4.3 Malnutrition 
The prevalence of hypoalbuminemia is high among patients beginning dialysis, is of 
multifactorial origin, and is associated with poor outcome. Hypoalbuminemia may be 
a reflection of chronic inflammation rather than of nutrition in itself. Spontaneous 
intake of protein begins to decrease when the glomerular filtration rate falls below 50 
ml/min. Progressive decline in renal function causes decreased appetite, thereby 
increasing the risk of malnutrition. Hence early dietary review is important to avoid 
malnutrition. Adequate dialysis is also important in maintaining optimal nutrition 
(Parmar, 2002). 
 
The recommended daily protein intake for patients on HD is 1.2g/kg and for those on 
PD is 1.2-1.3 g/kg. The recommended daily energy intake for people on HD or PD is 
35 kcal/kg for those who are less than 60 years of age and 30 to 35 kcal/kg for 
individuals 60 years or older. For individuals with chronic renal failure (GFR < 25 
mL/min) who are not undergoing maintenance dialysis, the institution of a planned 
low-protein diet providing 0.60 g protein/kg/d should be considered. For individuals 
who will not accept such a diet or who are unable to maintain adequate dietary 
energy intake with such a diet, an intake of up to 0.75 g protein/kg/d may be 
prescribed (National Kidney Foundation, 2000).   
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1.3 Pharmacokinetic and pharmacodynamic in patients with renal 
impairment 
 
Patients with CKD constitute a population at high-risk for adverse drug reactions 
(ADRs) and drug-drug interactions. Drug dosing in these patients often proves to be 
a difficult task. Patients with CKD almost always require a large number of 
medications to treat comorbid conditions and complications. Patients with renal 
impairment often have alterations in their pharmacokinetic parameters, including 
drug absorption, distribution, protein-binding, biotransformation, and renal excretion 
(Swan and Bennett, 1992; Kappel and Calissi, 2002). Elimination of many drugs is 
dependent on renal filtration, secretion and reabsorption. Glomerular filtration is 
impaired by renal disease or aging. The clearance of drugs eliminated primarily by 
this mechanism is decreased by renal disease. Therefore, special consideration 
should be taken when these drugs are prescribed to patients with impaired renal 
function. Patients with severe renal insufficiency can experience accumulation of 
drug metabolites also, which can contribute to pharmacologic activity or toxicity. 
Patients can also have an altered pharmacodynamic response to a given drug because 
of the physiologic and biochemical changes associated with progressive renal 
insufficiency (Gabardi and Abramson, 2005; Perazella and Parikh, 2005). For ESRD 
patients on dialysis, some medications are removed during dialysis. All these 
changes should be considered when drugs are prescribed to patients with impaired 
renal functions. 
 
1.3.1 The effect of renal disease on drugs pharmacokinetics 
Clinical pharmacokinetics is the discipline that describes the absorption, distribution, 
metabolism, and elimination of drugs in patients requiring drug therapy. 
Pharmacokinetic concepts are important to individualize patient drug therapy. 
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Combined with a knowledge of the disease states and conditions that influence the 
disposition of a particular drug, kinetic concepts can be used to modify doses to 
produce serum drug concentrations that result in desirable pharmacologic effects 
without unwanted side effects. Many factors must be taken into consideration when 
deciding on the best drug dose for a patient including  age,  gender, weight, other 
drug therapy, disease states and conditions (DiPiro et al., 2005). The followings need 
to considered in patients with CKD: 
 
1.3.1.1 Effects on absorption 
A medication’s oral bioavailability is defined as the fraction of an administered dose 
that reaches the systemic circulation. This pharmacokinetic parameter may be 
influenced by numerous physiologic changes in the gastrointestinal tract, several of 
which are commonly seen in the CKD population (Gabardi and Abramson, 2005). 
These changes include changes in gastric pH, gastroparesis, bowel wall edema, 
vomiting, diarrhea, and reduced intestinal metabolism and transport. 
 
Increased gastric pH is a common manifestation of CKD. The etiology of this finding 
is multifactorial. One explanation for increased pH is ammonia formation in the gut 
secondary to the conversion of salivary urea by urease enzymes. The administration 
of phosphate binders, antacids, H2-receptor antagonists, and proton-pump inhibitors 
in this patient population is common. For medications that are best absorbed in an 
acidic environment, increased gastric pH often reduces drug dissolution, ionization, 
and bioavailability. Examples include furosemide, ketoconazole and ferrous sulphate 
(Kappel and Calissi, 2002; Gabardi and Abramson, 2005; Perazella and Parikh, 
2005). 
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It has been shown that the administration of magnesium hydroxide and sodium 
bicarbonate can enhance the absorption of some weakly acidic molecules (e.g., 
ibuprofen, glipizide, glyburide, and tolbutamide) by increasing their water solubility 
and subsequent absorption. The ingestion of cation-containing antacids (e.g., calcium 
and magnesium), aluminium hydroxide, sodium polystyrene sulfonate, and iron may 
reduce drug absorption because of chelation of other medications and the formation 
of insoluble compounds. Fluoroquinolones and tetracyclines are two medication 
classes that are highly susceptible to chelate formation in patients with renal 
insufficiency (Kappel and Calissi, 2002; Nolin et al., 2003; Gabardi and Abramson, 
2005; Perazella and Parikh, 2005). 
 
Many patients with renal insufficiency suffer from gastroparesis, which can result in 
delayed gastric emptying. Though delayed emptying may prolong the time to 
maximum drug concentration, these delays generally do not affect the overall extent 
of absorption (Nolin et al., 2003; Gabardi and Abramson, 2005; Perazella and 
Parikh, 2005). However, these delays might be important for drugs such as short-
acting sulfonylureas (Kappel and Calissi, 2002). 
 
Bowel wall edema has also been reported as a potential cause of diminished oral 
absorption in CKD patients (Swan et al., 1992; Kappel and Calissi, 2002; Nolin et 
al., 2003; and Abramson, 2005)  
 
Vomiting and diarrhoea are also common in CKD patients and can reduce the 
amount of drug absorbed (Swan and Bennett, 992; Kappel and Calissi, 2002; DiPiro 
et al., 2005). 
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CKD-induced reductions in intestinal metabolism and P-glycoprotein–mediated drug 
transport may result in increased oral bioavailability of certain medications. Several 
medications undergo significant metabolism in the gastrointestinal tract, including 
cyclosporine and tacrolimus. Renal insufficiency is associated with decreased 
intestinal cytochrome P 450 (CYP450) enzymes activity. This altered activity is 
thought to be secondary to diminished CYP450 gene expression. CKD-induced 
reductions in intestinal CYP450 biotransformation have a profound effect on drug 
absorption by increasing overall oral absorption. P-glycoprotein is a transport protein 
that plays a vital role in drug-disposition. This protein is found in several areas of the 
body, including the intestines, liver, and kidneys. P-glycoprotein functions to protect 
the body against the accumulation of toxic compounds by transporting these 
compounds out of the systemic circulation and into the intestinal lumen, bile, or 
urine. Several animal models of CKD have demonstrated decreased activity of 
intestinal P-glycoprotein. Decreased P-glycoprotein activity results in a greater 
concentration of medications remaining in the systemic circulation (Nolin et al., 
2003; Gabardi and Abramson, 2005). 
 
Unfortunately, there is little quantitative information regarding the influence of 
impaired renal function on drug absorption and bioavailability (DiPiro et al., 2005). 
Physicians and pharmacists need to modify the regimens according to the patient’s 
response. 
 
1.3.1.2 Effects on distribution 
CKD-induced alterations in protein binding can have clinical implications. 
Medications that are acidic (e.g., barbiturates, cephalosporins, furosemide, 
